Reagila

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0035	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	11/03/2025		SmPC and PL	
X/0033	Annex I_2.(d) Change or addition of a new pharmaceutical form	30/05/2024	01/08/2024	SmPC, Labelling and	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

				PL	
II/0034	Update of sections 4.3, 4.4 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	11/04/2024	01/08/2024	SmPC and PL	Please refer to Scientific Discussion Reagila-H/C/002770/II/0034. For more information, please refer to the Summary of Product Characteristics. Update of sections 4.3, 4.4 and 4.5 of the SmPC to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on results from a study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The Package Leaflet is updated accordingly.
PSUSA/10623 /202210	Periodic Safety Update EU Single assessment - cariprazine	12/05/2023	n/a		PRAC Recommendation - maintenance
IB/0032	B.II.e.z - Change in container closure system of the Finished Product - Other variation	28/03/2023	n/a		
IA/0031	A.7 - Administrative change - Deletion of manufacturing sites	09/03/2023	n/a		
IB/0027	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	09/06/2022	n/a		

N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	02/06/2022	23/01/2023	PL	
IAIN/0028/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	02/05/2022	n/a		
R/0026	Renewal of the marketing authorisation.	27/01/2022	04/04/2022	SmPC, Annex II and PL	Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of Reagila in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity.
II/0023	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	10/02/2022	23/01/2023	SmPC and PL	
II/0020/G	This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging	16/12/2021	n/a		

	site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site				
II/0022	B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes	18/11/2021	n/a		
IB/0024/G	This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	26/10/2021	04/04/2022	SmPC, Labelling and PL	

IB/0021/G	This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	13/10/2021	n/a		
IA/0025	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	21/09/2021	n/a		
N/0019	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/07/2021	04/04/2022	PL	
PSUSA/10623 /202010	Periodic Safety Update EU Single assessment - cariprazine	06/05/2021	n/a		PRAC Recommendation - maintenance
N/0016	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/10/2020	04/04/2022	PL	

PSUSA/10623 /201910	Periodic Safety Update EU Single assessment - cariprazine	17/04/2020	n/a		PRAC Recommendation - maintenance
PSUSA/10623 /201904	Periodic Safety Update EU Single assessment - cariprazine	31/10/2019	n/a		PRAC Recommendation - maintenance
II/0010	Submission of in vitro metabolism study report (R188-A15) and consequential update of the Risk Management Plan (version 1.7). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	03/10/2019	n/a		
IB/0014	B.I.z - Quality change - Active substance - Other variation	19/09/2019	n/a		
IB/0013	B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	19/09/2019	n/a		
IA/0011/G	This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability -	29/05/2019	n/a		

	Deletion of certificates (in case multiple certificates exist per material)				
PSUSA/10623 /201810	Periodic Safety Update EU Single assessment - cariprazine	16/05/2019	n/a		PRAC Recommendation - maintenance
PSUSA/10623 /201804	Periodic Safety Update EU Single assessment - cariprazine	31/10/2018	n/a		PRAC Recommendation - maintenance
II/0008	B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	13/09/2018	n/a		
PSUSA/10623 /201710	Periodic Safety Update EU Single assessment - cariprazine	17/05/2018	n/a		PRAC Recommendation - maintenance
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/05/2018	12/12/2018	PL	
IB/0004/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside	18/12/2017	12/12/2018	SmPC, Labelling and PL	

	the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes				
IA/0001/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	15/09/2017	n/a		